NBY — NovaBay Pharmaceuticals Inc
NYSE MKT · Healthcare · Biotechnology
NovaBay Pharmaceuticals Inc (NBY) is a biotechnology company listed on NYSE MKT. It is led by Michael Kazley, based in 2000 Powell Street, Emeryville, CA, United States, 94608, with about 2 employees. NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Net income was -$1.3M. NBY currently screens at market cap $51.9M.
Use this NBY page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NBY quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NBY SEC filings page. Lician reads the product cache first so this HTML stays unique to NovaBay Pharmaceuticals Inc even when a live quote feed is slow.
About NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals, Inc. engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
NBY Key Statistics
Market Cap
$51.92M
EPS
$0.00
Revenue
$0.00
Net Income
-$7.22M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
2
NBY Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.22M | -$9.64M | -$10.61M | -$5.82M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$3.42M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$430.00K
Operating Cash Flow
$0.00
Free Cash Flow
$0.00
NovaBay Pharmaceuticals Inc Company Information
- Chairman & CEO
- Michael Kazley
- Headquarters
- 2000 Powell Street, Emeryville, CA, United States, 94608
- Website
- novabay.com
- Phone
- 510 899 8800
- IPO / Founded
- 2007-10-26
- Sector
- Healthcare
- Industry
- Biotechnology